The world wide economic crisis did not manage to stop China’s biomedicine industry from enlarging and thriving. This resulted in a value output of about RMB 870 billion in 2008 which accumulated to a 25.23 % growth rate on a year to year basis. The success can be related to the heavy investments made by MNCs and the Chinese government in R&D centers within the past decade. Furthermore, biomedicine has a strong demand within the world ensuring foreign capital through exports. This lead to the fact that the key Chinese companies operating in this industry raised their total income of investment to over RMB 1.5 billion an increase of over 240 % compared to the same period last year.

According to business analysts, China’s biomedicine market has tremendous potential with predicted growth rates of 15 – 20 % for the foreseeable future of the next 5 years. Back in 2000 the market value already accounted for US $15.0 billion and is forecasted to top US $120 billion in 2020, hence leaving the United States behind and becoming the number one in the market.

R&D conducted in China has come to the attention of many MNCs, in addition to the previous focus on production and sales, as there are great ways of reducing costs and introduce new products to the market.

 Previous  |  Next            View all headlines